Skip to content

Perfusion Parameters and Outcome During a Standardized Deresuscitation Strategy with Net Ultrafiltration: a Retrospective Cohort Study.

Perfusion Parameters and Outcome During a Standardized Deresuscitation Strategy with Net Ultrafiltration: a Retrospective Cohort Study.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06899880
Acronym
DeepCART
Enrollment
120
Registered
2025-03-28
Start date
2024-01-01
Completion date
2024-04-01
Last updated
2025-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Continuous Renal Replacement Therapy, Fluid Overload

Brief summary

Hemodynamic tolerance of fluid removal during deresuscitation is a cornerstone of the impact on outcome of such a strategy. However, how to define and to predict hemodynamic tolerance to fluid removal remains controversial. The investigators routinely use a standardized deresuscitation protocol in patients with fluid overload and continuous renal replacement therapy combined with monitoring of clinical and biological perfusion parameters. The aim of the study was to describe perfusion during deresuscitation, and to determine whether it is associated with major adverse kidney events at day 30.

Interventions

OTHERDescribe the perfusion parameters during a deresuscitation strategy and their association with the outcome.

Arterial lactate, pCO2 gap, SvO2, capillary refill time and mottling score anomalies will be described during the first 5 days of the deresuscitation strategy.

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Age ≥ 18 years old * Acute kidney injury requiring continuous renal replacement therapy * Standardized deresuscitation following a routine care protocol

Exclusion criteria

* Chronic hemodialysis * Advanced directives to withhold or withdraw life-sustaining treatment, * Patient's opposition to the use of his/her personal health data

Design outcomes

Primary

MeasureTime frameDescription
MAKE 30A day 30 after the initiation of the deresuscitation strategyMajor adverse kidney event at day 30, defined as follows: * Death OR * No weaning of renal replacement therapy OR * Serum creatinine \> 2 times baseline serum creatinine

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026